Table 3 Clinical performance of current screening methods and models for screening cohorts at baseline (CIN2+)
| Â | Â | Sensitivity % (95% CI) | Specificity % (95% CI) | AUC (95% CI) | Referral rate % (95% CI) |
|---|---|---|---|---|---|
Screening cohort I (N = 3179) | Â | Â | Â | Â | |
HPV | hrHPV mRNA | 97.44 (93.59–100.00) | 85.94 (84.65–87.20) | 0.92 (0.90–0.94) | 16.14 (14.87–17.46) |
Senior cytologists | ASC-US | 87.18 (79.49–93.59) | 91.45 (90.52–92.39) | 0.89 (0.86–0.93) | 10.47 (9.43–11.59) |
Co-testing | 100.00 | 81.39 (80.01–82.75) | 0.91 (0.90–0.91) | 20.64 (19.24–22.08) | |
Base model | 100.00 | 84.49 (83.23–85.75) | 0.92 (0.92–0.93) | 17.55 (16.24–18.92) | |
Base model + E6 | 93.59 (87.18–98.72) | 92.26 (91.29–93.20) | 0.93 (0.90–0.96) | 9.81 (8.80–10.90) | |
Base model + GT | 97.44 (93.59–100.00) | 89.39 (88.26–90.42) | 0.93 (0.92–0.95) | 12.77 (11.63–13.98) | |
Base model + E6 + GT | 97.44 (93.59–100.00) | 89.04 (87.91–90.07) | 0.93 (0.91–0.95) | 13.09 (11.93–14.31) | |
Junior cytologists | ASC-US | 85.90 (78.21–93.59) | 87.39 (86.20–88.55) | 0.87 (0.83–0.91) | 14.38 (13.17–15.64) |
Co-testing | 100.00 | 77.91 (76.46–79.26) | 0.89 (0.88–0.90) | 24.03 (22.56–25.56) | |
Base model | 100.00 | 83.49 (82.20–84.78) | 0.92 (0.91–0.92) | 18.56 (17.22–19.96) | |
Base model + E6 | 91.03 (84.62–96.19) | 91.97 (91.04–92.94) | 0.92 (0.88–0.95) | 10.07 (9.04–11.16) | |
Base model + GT | 96.15 (91.03–100.00) | 88.39 (87.23–89.49) | 0.92 (0.90–0.94) | 13.68 (12.51–14.93) | |
Base model + E6 + GT | 96.15 (91.03–100.00) | 87.81 (86.62–88.94) | 0.92 (0.90–0.94) | 14.22 (13.02–15.48) | |
Screening cohort II (N = 3082) | Â | Â | Â | Â | |
HPV | hrHPV DNA | 90.20 (82.30–98.04) | 84.16 (82.88–85.42) | 0.87 (0.83–0.91) | 17.07 (15.75–18.44) |
Senior cytologists | ASC-US | 96.08 (90.20–100.00) | 83.90 (82.55–85.19) | 0.90 (0.87–0.93) | 17.46 (16.13–18.84) |
Co-testing | 100.00 | 74.40 (72.81–76.01) | 0.87 (0.86–0.88) | 26.83 (25.28–28.44) | |
Base model | 94.12 (86.27–100.00) | 94.06 (93.20–94.89) | 0.94 (0.91–0.97) | 7.40 (6.50–8.38) | |
Base model + GT | 96.08 (90.20–100.00) | 95.17 (94.34–95.93) | 0.96 (0.93–0.98) | 6.33 (5.49–7.25) | |
Junior cytologists | ASC-US | 90.20 (80.39–98.04) | 80.53 (79.18–81.95) | 0.85 (0.81–0.90) | 20.64 (19.22–22.11) |
Co-testing | 98.04 (94.12–100.00) | 71.16 (69.55–72.75) | 0.85 (0.83–0.87) | 29.98 (28.37–31.63) | |
Base model | 88.24 (78.43–96.08) | 90.76 (89.74–91.82) | 0.90 (0.85–0.94) | 10.55 (9.48–11.68) | |
Base Model+GT | 98.04 (94.12–100.00) | 89.64 (88.55–90.70) | 0.94 (0.92–0.96) | 11.78 (10.66–12.97) | |